MM075

IMPACT OF MUC1 AND PDL-1 EXPRESSION IN MULTIPLE MYELOMA PATIENTS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS

MM 075

Hussein Y.1, Sadeq Y.2, Shabana A.3

1 Clinical Immuno-Hematology Unit, Internal Medicine Department, Metghamr Cancer Center, Egypt.
2 Hematology Unit, Clinical Pathology Department, Mansoura Faculty of Medicine, Egypt.
3 Rheumatology department, Mansoura University Hospital, Egypt.

Introduction

PD-L1 is a negative regulator of immune activation that is upregulated in multiple myeloma. Disease progression and treatment relapse are attributed to MM cancer stem cells (CSCs) and signaling molecules such as MUC1.

Aim

Prognostic value of MUC1 and PDL-1 in MM complicated SLE

Objectives

20 newly diagnosed MM in SLE patients with a median 36 months follow up.

Asses Impact of MUC1 and PDL-1 expression on ORR, PFS, OS.


Methods

20 SLE patients on Hydroxychloroquine and steroid ± cyclosporine developed myeloma events with underlying plasma cell proliferative and ≥ 1 SLiM-CRAB features.

MUC1 and PDL-1 IHC expression in bone marrow biopsy.

Results

All patients showed BM plasma cells infiltration. SLAM index showed high disease activity (SLAM>6) so all patients considered myeloma non transplant eligible and started Lenalidomide plus dexamethasone.




SLAM index for SLE after three months of treatment


After three months, 11 (55%) patients showed partial response (IMWG response criteria) with SLAM≤6 in seven of them (63.3%) .

Sex months later, 13 (65%) patients showed complete response; sex of them (46.1%) patients had improved lupus activity (SLAM≤6).

Both MUC1 and PDL-1 expression associated with poor response to myeloma treatment (P=0.04 and 0.002, respectively) and high lupus disease activity (SLAM>6) (p= 0.001 and 0.01, respectively). With a median 36 months follow up; myeloma patients with MUC1 and PDL-1 expression associated with poor median PFS (p= 0.06 and 0.04, respectively) and poor median OS (p=0.05 and 0.001, respectively).



PFS of Positive PDL! Versus Negative PDL1



OS of Positive PDL! Versus Negative PDL1

Summary

Both MUC1 and PDL-1 expression linked to poor ORR, PFS, OS and SLAM index in SLE patients complicated with MM.

Discussion

We can validate these results in future research on large number of patients and could be used as risk stratification.

References

1. Jing Yang 1, Ling Meng 1, Yongxin Yang et al. Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort. Nucleosides Nucleotides Nucleic Acids . 2024;43(3):230-248

2. Li Yin 1, Ashujit Tagde 1, Reddy Gali et al. MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 Sep;178(6):914-926.

Hussein YA, Metghamr Cancer Center, Egypt
Hussein_adel@mans.edu.eg